During a discussion with colleagues about the best way to select small and new biotechnology firms for investment purposes, we started our answer by stating that selecting small and new biotechnology firms for investments is extremely challenging. As a matter of fact, the choice of firms for investment cannot be guaranteed approval of the firms’ products based on early and mid clinical trials' promising results, including beating the placebo or offering proofs of concepts.   

Our choices are firms that have just one, approved, unique, safe and effective product that saved a large number of patients from devastation. Better even if . . .